Scenic Biotech Joins Michael J. Fox Foundation’s LITE Program to Explore New Disease-Modifying Approach for Parkinson’s Disease
- Collaboration will evaluate Scenic’s first-in-class PLA2G15 inhibitor program in Parkinson’s disease
- Leveraging MJFF’s LITE consortium and world-class LRRK2 biology and biomarker infrastructure to test improving lysosomal health as a therapeutic angle for Parkinson’s disease
Amsterdam, The Netherlands — 11 June, 2026: Scenic Biotech (“Scenic” or “the Company”), a neurometabolic company whose function‑first genomics engine has identified a first-in-class therapy to restore lysosomal function, a core driver of neurodegeneration, today announced it has joined The Michael J. Fox Foundation for Parkinson’s Research (MJFF) LRRK2 Investigative Therapeutics Exchange (LITE) program.
